Now showing items 1-20 of 28

    • Abiraterone for Prostate Cancer Not Previously Treated with Hormone Therapy. 

      James, ND; de Bono, JS; Spears, MR; Clarke, NW; Mason, MD; Dearnaley, DP; Ritchie, AWS; Amos, CL; Gilson, C; Jones, RJ; Matheson, D; Millman, R; Attard, G; Chowdhury, S; Cross, WR; Gillessen, S; Parker, CC; Russell, JM; Berthold, DR; Brawley, C; Adab, F; Aung, S; Birtle, AJ; Bowen, J; Brock, S; Chakraborti, P; Ferguson, C; Gale, J; Gray, E; Hingorani, M; Hoskin, PJ; Lester, JF; Malik, ZI; McKinna, F; McPhail, N; Money-Kyrle, J; O'Sullivan, J; Parikh, O; Protheroe, A; Robinson, A; Srihari, NN; Thomas, C; Wagstaff, J; Wylie, J; Zarkar, A; Parmar, MKB; Sydes, MR; STAMPEDE Investigators (2017-07)
      BACKGROUND:Abiraterone acetate plus prednisolone improves survival in men with relapsed prostate cancer. We assessed the effect of this combination in men starting long-term androgen-deprivation therapy (ADT), using a ...
    • Adding abiraterone or docetaxel to long-term hormone therapy for prostate cancer: directly randomised data from the STAMPEDE multi-arm, multi-stage platform protocol. 

      Sydes, MR; Spears, MR; Mason, MD; Clarke, NW; Dearnaley, DP; de Bono, JS; Attard, G; Chowdhury, S; Cross, W; Gillessen, S; Malik, ZI; Jones, R; Parker, CC; Ritchie, AWS; Russell, JM; Millman, R; Matheson, D; Amos, C; Gilson, C; Birtle, A; Brock, S; Capaldi, L; Chakraborti, P; Choudhury, A; Evans, L; Ford, D; Gale, J; Gibbs, S; Gilbert, DC; Hughes, R; McLaren, D; Lester, JF; Nikapota, A; O'Sullivan, J; Parikh, O; Peedell, C; Protheroe, A; Rudman, SM; Shaffer, R; Sheehan, D; Simms, M; Srihari, N; Strebel, R; Sundar, S; Tolan, S; Tsang, D; Varughese, M; Wagstaff, J; Parmar, MKB; James, ND; STAMPEDE Investigators (2018-05)
      Background:Adding abiraterone acetate with prednisolone (AAP) or docetaxel with prednisolone (DocP) to standard-of-care (SOC) each improved survival in systemic therapy for advanced or metastatic prostate cancer: evaluation ...
    • Adding Celecoxib With or Without Zoledronic Acid for Hormone-Naïve Prostate Cancer: Long-Term Survival Results From an Adaptive, Multiarm, Multistage, Platform, Randomized Controlled Trial. 

      Mason, MD; Clarke, NW; James, ND; Dearnaley, DP; Spears, MR; Ritchie, AWS; Attard, G; Cross, W; Jones, RJ; Parker, CC; Russell, JM; Thalmann, GN; Schiavone, F; Cassoly, E; Matheson, D; Millman, R; Rentsch, CA; Barber, J; Gilson, C; Ibrahim, A; Logue, J; Lydon, A; Nikapota, AD; O'Sullivan, JM; Porfiri, E; Protheroe, A; Srihari, NN; Tsang, D; Wagstaff, J; Wallace, J; Walmsley, C; Parmar, MKB; Sydes, MR; STAMPEDE Investigators (2017-05)
      Purpose Systemic Therapy for Advanced or Metastatic Prostate Cancer: Evaluation of Drug Efficacy is a randomized controlled trial using a multiarm, multistage, platform design. It recruits men with high-risk, locally ...
    • Circulating Metabolic Biomarkers of Screen-Detected Prostate Cancer in the ProtecT Study. 

      Adams, CD; Richmond, R; Ferreira, DLS; Spiller, W; Tan, V; Zheng, J; Würtz, P; Donovan, J; Hamdy, F; Neal, D; Lane, JA; Smith, GD; Relton, C; Eeles, RA; Haiman, CA; Kote-Jarai, Z; Schumacher, FR; Olama, AAA; Benlloch, S; Muir, K; Berndt, SI; Conti, DV; Wiklund, F; Chanock, SJ; Gapstur, S; Stevens, VL; Tangen, CM; Batra, J; Clements, JA; Gronberg, H; Pashayan, N; Schleutker, J; Albanes, D; Wolk, A; West, CML; Mucci, LA; Cancel-Tassin, G; Koutros, S; Sorensen, KD; Maehle, L; Travis, RC; Hamilton, RJ; Ingles, SA; Rosenstein, BS; Lu, Y-J; Giles, GG; Kibel, AS; Vega, A; Kogevinas, M; Penney, KL; Park, JY; Stanford, JL; Cybulski, C; Nordestgaard, BG; Brenner, H; Maier, C; Kim, J; John, EM; Teixeira, MR; Neuhausen, SL; De Ruyck, K; Razack, A; Newcomb, LF; Lessel, D; Kaneva, RP; Usmani, N; Claessens, F; Townsend, PA; Dominguez, MG; Roobol, MJ; Menegaux, F; Khaw, K-T; Cannon-Albright, LA; Pandha, H; Thibodeau, SN; Martin, RM; PRACTICAL consortium (2019-01)
      BACKGROUND:Whether associations between circulating metabolites and prostate cancer are causal is unknown. We report on the largest study of metabolites and prostate cancer (2,291 cases and 2,661 controls) and appraise ...
    • DESNT: A Poor Prognosis Category of Human Prostate Cancer. 

      Luca, B-A; Brewer, DS; Edwards, DR; Edwards, S; Whitaker, HC; Merson, S; Dennis, N; Cooper, RA; Hazell, S; Warren, AY; CancerMap Group; Eeles, R; Lynch, AG; Ross-Adams, H; Lamb, AD; Neal, DE; Sethia, K; Mills, RD; Ball, RY; Curley, H; Clark, J; Moulton, V; Cooper, CS (2018-12)
      BACKGROUND:A critical problem in the clinical management of prostate cancer is that it is highly heterogeneous. Accurate prediction of individual cancer behaviour is therefore not achievable at the time of diagnosis leading ...
    • Diethylstilbestrol in castration-resistant prostate cancer. 

      Wilkins, A; Shahidi, M; Parker, C; Gunapala, R; Thomas, K; Huddart, R; Horwich, A; Dearnaley, D (2012-12)
      What's known on the subject? and What does the study add? Diethylstilbestrol (DES) was the first hormone treatment used for prostate cancer and has also shown effectiveness in castration-resistant disease in small studies; ...
    • Effect on Overall Survival of Locoregional Treatment in a Cohort of De Novo Metastatic Prostate Cancer Patients: A Single Institution Retrospective Analysis From the Royal Marsden Hospital. 

      Bianchini, D; Lorente, D; Rescigno, P; Zafeiriou, Z; Psychopaida, E; O'Sullivan, H; Alaras, M; Kolinsky, M; Sumanasuriya, S; Sousa Fontes, M; Mateo, J; Perez Lopez, R; Tunariu, N; Fotiadis, N; Kumar, P; Tree, A; Van As, N; Khoo, V; Parker, C; Eeles, R; Thompson, A; Dearnaley, D; de Bono, JS (2017-10)
      The optimal management of the primary tumor in metastatic at diagnosis (M1) prostate cancer (PCa) patients is not yet established. We retrospectively evaluated the effect of locoregional treatment (LRT) on overall survival ...
    • Efficacy of low-dose dexamethasone in castration-refractory prostate cancer. 

      Venkitaraman, R; Thomas, K; Huddart, RA; Horwich, A; Dearnaley, DP; Parker, CC (2008-02)
      To evaluate the prostate-specific antigen (PSA) response rate and duration of PSA response to dexamethasone in patients with castration-refractory prostate cancer (CRPC), as corticosteroids are frequently used as second-line ...
    • Failure-Free Survival and Radiotherapy in Patients With Newly Diagnosed Nonmetastatic Prostate Cancer: Data From Patients in the Control Arm of the STAMPEDE Trial. 

      James, ND; Spears, MR; Clarke, NW; Dearnaley, DP; Mason, MD; Parker, CC; Ritchie, AWS; Russell, JM; Schiavone, F; Attard, G; de Bono, JS; Birtle, A; Engeler, DS; Elliott, T; Matheson, D; O'Sullivan, J; Pudney, D; Srihari, N; Wallace, J; Barber, J; Syndikus, I; Parmar, MKB; Sydes, MR; STAMPEDE Investigators (2016-03)
      IMPORTANCE:The natural history of patients with newly diagnosed high-risk nonmetastatic (M0) prostate cancer receiving hormone therapy (HT) either alone or with standard-of-care radiotherapy (RT) is not well documented. ...
    • Genetic predisposition to prostate cancer. 

      Benafif, S; Eeles, R (2016-12)
      INTRODUCTION:Prostate cancer (PrCa) is the commonest non-cutaneous cancer in men in the UK. Epidemiological evidence as well as twin studies points towards a genetic component contributing to aetiology. SOURCES OF DATA:Key ...
    • Ki67 Is an Independent Predictor of Recurrence in the Largest Randomized Trial of 3 Radiation Fractionation Schedules in Localized Prostate Cancer. 

      Wilkins, AC; Gusterson, B; Szijgyarto, Z; Haviland, J; Griffin, C; Stuttle, C; Daley, F; Corbishley, CM; Dearnaley, DP; Hall, E; Somaiah, N; CHHiP Trial Investigators (2018-06)
      PURPOSE:To assess whether the cellular proliferation marker Ki67 provides prognostic information and predicts response to radiation therapy fractionation in patients with localized prostate tumors participating in a ...
    • Management of Men with Prostate-specific Antigen Failure After Prostate Radiotherapy: The Case Against Early Androgen Deprivation. 

      Brand, D; Parker, C (2018-04)
      In men with prostate-specific antigen failure after radical radiotherapy, androgen deprivation therapy should be delayed until the site of recurrence is known to allow consideration of curative treatment options, to delay ...
    • Managing Nonmetastatic Castration-resistant Prostate Cancer. 

      Mateo, J; Fizazi, K; Gillessen, S; Heidenreich, A; Perez-Lopez, R; Oyen, WJG; Shore, N; Smith, M; Sweeney, C; Tombal, B; Tomlins, SA; de Bono, JS (2019-02)
      CONTEXT:Patients with nonmetastatic castration-resistant prostate cancer (nmCRPC) have rising prostate-specific antigen (PSA) and castrate testosterone levels, with no radiological findings of metastatic disease on computed ...
    • Neutrophil to Lymphocyte Ratio in Castration-Resistant Prostate Cancer Patients Treated With Daily Oral Corticosteroids. 

      Mehra, N; Sharp, A; Lorente, D; Dolling, D; Sumanasuriya, S; Johnson, B; Dearnaley, D; Parker, C; de Bono, J (2017-12)
      BACKGROUND:The neutrophil to lymphocyte ratio (NLR) has been shown to be highly prognostic across many tumor types, and predictive of treatment outcome in advanced prostate cancer, and has been postulated to be an indirect ...
    • Nine-year Follow-up for a Study of Diffusion-weighted Magnetic Resonance Imaging in a Prospective Prostate Cancer Active Surveillance Cohort. 

      Henderson, DR; de Souza, NM; Thomas, K; Riches, SF; Morgan, VA; Sohaib, SA; Dearnaley, DP; Parker, CC; van As, NJ (2016-06)
      In active surveillance (AS) for prostate cancer there are few data on long-term outcomes associated with novel imaging markers.To determine long-term outcomes with respect to the apparent diffusion coefficient (ADC) derived ...
    • Patterns of recurrence after prostate bed radiotherapy. 

      Brand, DH; Parker, JI; Dearnaley, DP; Eeles, R; Huddart, R; Khoo, V; Murray, J; Suh, Y-E; Tree, AC; van As, N; Parker, C (2019-12)
      BACKGROUND AND PURPOSE:Prostate bed radiotherapy is a standard treatment after radical prostatectomy. Recent evidence suggests that, for patients with a PSA > 0.34 ng/ml, the radiotherapy treatment volume should include ...
    • Phase 1/2 Dose-Escalation Study of the Use of Intensity Modulated Radiation Therapy to Treat the Prostate and Pelvic Nodes in Patients With Prostate Cancer. 

      Reis Ferreira, M; Khan, A; Thomas, K; Truelove, L; McNair, H; Gao, A; Parker, CC; Huddart, R; Bidmead, M; Eeles, R; Khoo, V; van As, NJ; Hansen, VN; Dearnaley, DP (2017-12)
      To investigate the feasibility of dose escalation and hypofractionation of pelvic lymph node intensity modulated radiation therapy (PLN-IMRT) in prostate cancer (PCa).In a phase 1/2 study, patients with advanced localized ...
    • Polygenic hazard score to guide screening for aggressive prostate cancer: development and validation in large scale cohorts. 

      Seibert, TM; Fan, CC; Wang, Y; Zuber, V; Karunamuni, R; Parsons, JK; Eeles, RA; Easton, DF; Kote-Jarai, Z; Al Olama, AA; Garcia, SB; Muir, K; Grönberg, H; Wiklund, F; Aly, M; Schleutker, J; Sipeky, C; Tammela, TL; Nordestgaard, BG; Nielsen, SF; Weischer, M; Bisbjerg, R; Røder, MA; Iversen, P; Key, TJ; Travis, RC; Neal, DE; Donovan, JL; Hamdy, FC; Pharoah, P; Pashayan, N; Khaw, K-T; Maier, C; Vogel, W; Luedeke, M; Herkommer, K; Kibel, AS; Cybulski, C; Wokolorczyk, D; Kluzniak, W; Cannon-Albright, L; Brenner, H; Cuk, K; Saum, K-U; Park, JY; Sellers, TA; Slavov, C; Kaneva, R; Mitev, V; Batra, J; Clements, JA; Spurdle, A; Teixeira, MR; Paulo, P; Maia, S; Pandha, H; Michael, A; Kierzek, A; Karow, DS; Mills, IG; Andreassen, OA; Dale, AM; PRACTICAL Consortium* (2018-01-10)
      OBJECTIVES:To develop and validate a genetic tool to predict age of onset of aggressive prostate cancer (PCa) and to guide decisions of who to screen and at what age. DESIGN:Analysis of genotype, PCa status, and age to ...
    • Polygenic risk-tailored screening for prostate cancer: A benefit-harm and cost-effectiveness modelling study. 

      Callender, T; Emberton, M; Morris, S; Eeles, R; Eeles, R; Kote-Jarai, Z; Pharoah, PDP; Pashayan, N (2019-12-20)
      BACKGROUND:The United States Preventive Services Task Force supports individualised decision-making for prostate-specific antigen (PSA)-based screening in men aged 55-69. Knowing how the potential benefits and harms of ...
    • Predictors of histological disease progression in untreated, localized prostate cancer. 

      Venkitaraman, R; Norman, A; Woode-Amissah, R; Fisher, C; Dearnaley, D; Horwich, A; Huddart, R; Khoo, V; Thompson, A; Parker, C (2007-09)
      Active surveillance for early prostate cancer is a policy of close monitoring with radical treatment targeted at cases with evidence of disease progression. There is no consensus on the need for or optimum timing of repeat ...